1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56590
Full metadata record
DC FieldValueLanguage
dc.creatorBarbara Delano Cruzpt_BR
dc.creatorMariana M. Barbosapt_BR
dc.creatorLucas Torrespt_BR
dc.creatorPâmela Azevedopt_BR
dc.creatorVânia E. A. Silvapt_BR
dc.creatorBrian Godmanpt_BR
dc.creatorJuliana Alvares Teodoropt_BR
dc.date.accessioned2023-07-18T16:49:55Z-
dc.date.available2023-07-18T16:49:55Z-
dc.date.issued2021-
dc.citation.volume9pt_BR
dc.citation.spage505pt_BR
dc.citation.epage524pt_BR
dc.identifier.issn2366-1070pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56590-
dc.description.resumoIntroduction Lung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2–5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment. Objective To conduct a systematic review and meta-analysis to estimate the magnitude of the overall survival (OS) and progression-free survival (PFS) from using crizotinib as treatment compared to traditional chemotherapy to guide future decision making. Methods PRISMA and Cochrane recommendations were followed using the findings based on studies published in the main international electronic databases. Selection criteria included the following: randomized clinical trials (RCT) or cohort studies that had assessed the efficacy and effectiveness of crizotinib as monotherapy in patients with NSCLC with ALK fusions. Results From 2504 publications identified in the literature, only eight publications referring to seven studies met the selection criteria, with high heterogeneity identified between the studies. Overall, there was a significant gain in PFS (HR 0.38; 95% CI 0.30–0.49; p < 0.00001); however, there was no significant gain in OS (HR 0.68; 95% CI 0.43–1.08; p = 0.10). Conclusion The study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion, as previously reported. However, there was no increase in overall survival in patients with NSCLC with genetic alterations of ALK. This must be considered when reviewing and funding treatments for NSCLC patients with this mutation.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIALpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofOncology and Therapypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectAnaplastic lymphoma kinasept_BR
dc.subjectCrizotinibpt_BR
dc.subjectEffectivenesspt_BR
dc.subjectEfficacypt_BR
dc.subjectLung cancerpt_BR
dc.subjectSystematic reviewpt_BR
dc.subject.otherEficáciapt_BR
dc.subject.otherMeta-analisespt_BR
dc.titleCrizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and MetaAnalysispt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://link.springer.com/article/10.1007/s40487-021-00155-3pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-4106-7768pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-7770-4597pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-1947-6290pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-6539-6972pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0210-0721pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer A Systematic Review and Meta-Analysis.pdf7.83 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.